Market Cap 10.46B
Revenue (ttm) 0.00
Net Income (ttm) -1.08B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,072,920
Avg Vol 5,024,712
Day's Range N/A - N/A
Shares Out 797.75M
Stochastic %K 10%
Beta -1.23
Analysts Sell
Price Target $27.13

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 203 2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
BapoRothstein
BapoRothstein Aug. 21 at 8:06 PM
Did you Dr. Clow has never had a new drug application turned down by the FDA across her 30-year career? She’s credited with 19 successful NDA/BLA submissions and approvals across oncology, cardiovascular, and neurology, including leading the team that submitted the first fully electronic BLA in 1995. Harvard gave her its highest award and described her as being amongst the most productive and brilliant minds to have ever graced its academic institution. She is the one handling our application and direct communications with FDA staff. When they talk to her, they know they talking to someone much smarter, more prestigious, more accomplished, and more respected than they will ever be. Consider this the next time you read what some lightweight on the internet has to say about $SMMT’s chances of approval. Bob isn’t fucking around. This isn’t some moonshot built on hopes and dreams. This is Bob’s well-designed plan coming to life, the grand final act in his storied biotech business career.
0 · Reply
gtfo9000
gtfo9000 Aug. 21 at 6:56 PM
$SMMT all bs to steal your shares , hold for gold
0 · Reply
TruthBroker2
TruthBroker2 Aug. 21 at 6:16 PM
0 · Reply
BigBeardTrader
BigBeardTrader Aug. 21 at 5:50 PM
$SMMT The bottom line. If Ivo keeps people alive longer, and the updated curves say it does, then rejecting it means the FDA picked the rulebook over real patients who have nothing else and it's the kind of pressure that can push the FDA toward approval. That's what I'm betting on in the short run.
2 · Reply
BigBeardTrader
BigBeardTrader Aug. 21 at 5:09 PM
$SMMT Not sure why @CoconutTrader3000 blocked me, but He's not wrong. Filing the BLA without OS is risky and completely Duggan's MO. He wants to be the first PD-1xVEGF with US approval. Approval makes raising capital much easier at higher valuations and dilutes shareholders less, not to mention they will have the best in class approved drug. Duggan sees a higher risk/reward for filing early. But realize the risk here of disapproval is completely separate from how well Ivonescimab works. I for one think the FDA will approve and I have a lot of capital riding on that bet. But it can go the other way and the stock tanks, but I'll probably pick up more shares to be honest. 50 mil bet by Duggan at 13 says more to me than trying to decode if the FDA will approve without stat sig OS. Which as I posted earlier, did eventually happen in REALITY...Disapproval on a technicality seems unlikely.
1 · Reply
RadioIsotope25
RadioIsotope25 Aug. 21 at 5:05 PM
The imaging work that proved RAD204 would work in patients therapeutically. Now we are going to reap the rewards. $RADX $SMMT https://chatgpt.com/s/m_6a888518ef70819188146addca1ea251
0 · Reply
CoconutTrader3000
CoconutTrader3000 Aug. 21 at 3:40 PM
$SMMT Question, in a recent SEC release (or somewhat recently) SMMT disclosed the FDA basically told them they need OS for approval. Well, we know the study they submitted for BLA didn't hit OS, and still hasn't hit OS, and even if it did it doesn't technically count if it didn't meet it by the designs of the trial and data cuts, why are people thinking approval has a good chance of happening when we know the trial they submitted didn't reach that goal? Not trying to be a bear, I know the typical response here is that the FDA takes a lot into consideration, but they literally told SMMT this time they're not doing that, and they need OS. Doesn't that kinda mean they won't get approval?
1 · Reply
danefiori
danefiori Aug. 21 at 3:35 PM
$SMMT 🚀
0 · Reply
danefiori
danefiori Aug. 21 at 2:59 PM
$SMMT massive insider buy of 3.81 million shares. Super bearish. We are within the 90 day FDA Approval window
1 · Reply
SmokeWagon
SmokeWagon Aug. 21 at 2:02 PM
$SMMT !!!
0 · Reply
Latest News on SMMT
Summit Therapeutics falls -8.5%

2026-08-17T14:05:25.000Z - 4 days ago

Summit Therapeutics falls -8.5%


Summit Therapeutics Earnings Call Transcript: Q2 2026

Jul 23, 2026, 4:30 PM EDT - 4 weeks ago

Summit Therapeutics Earnings Call Transcript: Q2 2026


Summit Therapeutics Earnings release: Q2 2026

Jul 23, 2026, 4:30 PM EDT - 4 weeks ago

Summit Therapeutics Earnings release: Q2 2026


Summit Therapeutics Quarterly report: Q2 2026

Jul 23, 2026, 4:30 PM EDT - 4 weeks ago

Summit Therapeutics Quarterly report: Q2 2026


Summit Therapeutics Slides: Q2 2026

Jul 23, 2026, 4:30 PM EDT - 4 weeks ago

Summit Therapeutics Slides: Q2 2026


Summit Therapeutics reports Q2 EPS (28c), consensus (21c)

2026-07-23T20:10:46.000Z - 4 weeks ago

Summit Therapeutics reports Q2 EPS (28c), consensus (21c)


Summit Therapeutics Transcript: AGM 2026

Jun 10, 2026, 8:30 AM EDT - 2 months ago

Summit Therapeutics Transcript: AGM 2026


The Era of the One-Size-Fits-All Cancer Drug Is Ending

Jun 6, 2026, 5:30 AM EDT - 2 months ago

The Era of the One-Size-Fits-All Cancer Drug Is Ending


Summit Therapeutics Transcript: Status update

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Summit Therapeutics Transcript: Status update


Summit Therapeutics Press release: Status update

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Summit Therapeutics Press release: Status update


Summit Therapeutics Slides: Status update

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Summit Therapeutics Slides: Status update


Summit Therapeutics Earnings release: Q1 2026

Apr 30, 2026, 4:00 PM EDT - 4 months ago

Summit Therapeutics Earnings release: Q1 2026


Summit Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 4:00 PM EDT - 4 months ago

Summit Therapeutics Quarterly report: Q1 2026


Summit Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Summit Therapeutics Proxy statement: Proxy filing


Summit Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Summit Therapeutics Proxy statement: Proxy filing


Summit Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Summit Therapeutics Proxy statement: Proxy filing


Summit Therapeutics to Present at Upcoming Investor Conferences

Feb 26, 2026, 6:45 PM EST - 6 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences


Summit Therapeutics Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Summit Therapeutics Earnings Call Transcript: Q4 2025


Summit Therapeutics Annual report: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Summit Therapeutics Annual report: Q4 2025


Summit Therapeutics Earnings release: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Summit Therapeutics Earnings release: Q4 2025


Summit Therapeutics Slides: Q4 2025

Feb 23, 2026, 4:30 PM EST - 6 months ago

Summit Therapeutics Slides: Q4 2025


Summit Therapeutics Raises $500 Million in Private Placement

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Raises $500 Million in Private Placement


Summit Therapeutics Earnings Call Transcript: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Earnings Call Transcript: Q3 2025


Summit Therapeutics Earnings release: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Earnings release: Q3 2025


Summit Therapeutics Quarterly report: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Quarterly report: Q3 2025


Summit Therapeutics Slides: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Summit Therapeutics Slides: Q3 2025


Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 16, 2025, 4:31 PM EDT - 1 year ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm


Summit Therapeutics Transcript: Study Update

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Summit Therapeutics Transcript: Study Update


Summit Therapeutics Press release: Study Update

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Summit Therapeutics Press release: Study Update


Summit Therapeutics Slides: Study Update

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Summit Therapeutics Slides: Study Update


Summit Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Summit Therapeutics Earnings release: Q2 2025


Summit Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Summit Therapeutics Quarterly report: Q2 2025


BapoRothstein
BapoRothstein Aug. 21 at 8:06 PM
Did you Dr. Clow has never had a new drug application turned down by the FDA across her 30-year career? She’s credited with 19 successful NDA/BLA submissions and approvals across oncology, cardiovascular, and neurology, including leading the team that submitted the first fully electronic BLA in 1995. Harvard gave her its highest award and described her as being amongst the most productive and brilliant minds to have ever graced its academic institution. She is the one handling our application and direct communications with FDA staff. When they talk to her, they know they talking to someone much smarter, more prestigious, more accomplished, and more respected than they will ever be. Consider this the next time you read what some lightweight on the internet has to say about $SMMT’s chances of approval. Bob isn’t fucking around. This isn’t some moonshot built on hopes and dreams. This is Bob’s well-designed plan coming to life, the grand final act in his storied biotech business career.
0 · Reply
gtfo9000
gtfo9000 Aug. 21 at 6:56 PM
$SMMT all bs to steal your shares , hold for gold
0 · Reply
TruthBroker2
TruthBroker2 Aug. 21 at 6:16 PM
0 · Reply
BigBeardTrader
BigBeardTrader Aug. 21 at 5:50 PM
$SMMT The bottom line. If Ivo keeps people alive longer, and the updated curves say it does, then rejecting it means the FDA picked the rulebook over real patients who have nothing else and it's the kind of pressure that can push the FDA toward approval. That's what I'm betting on in the short run.
2 · Reply
BigBeardTrader
BigBeardTrader Aug. 21 at 5:09 PM
$SMMT Not sure why @CoconutTrader3000 blocked me, but He's not wrong. Filing the BLA without OS is risky and completely Duggan's MO. He wants to be the first PD-1xVEGF with US approval. Approval makes raising capital much easier at higher valuations and dilutes shareholders less, not to mention they will have the best in class approved drug. Duggan sees a higher risk/reward for filing early. But realize the risk here of disapproval is completely separate from how well Ivonescimab works. I for one think the FDA will approve and I have a lot of capital riding on that bet. But it can go the other way and the stock tanks, but I'll probably pick up more shares to be honest. 50 mil bet by Duggan at 13 says more to me than trying to decode if the FDA will approve without stat sig OS. Which as I posted earlier, did eventually happen in REALITY...Disapproval on a technicality seems unlikely.
1 · Reply
RadioIsotope25
RadioIsotope25 Aug. 21 at 5:05 PM
The imaging work that proved RAD204 would work in patients therapeutically. Now we are going to reap the rewards. $RADX $SMMT https://chatgpt.com/s/m_6a888518ef70819188146addca1ea251
0 · Reply
CoconutTrader3000
CoconutTrader3000 Aug. 21 at 3:40 PM
$SMMT Question, in a recent SEC release (or somewhat recently) SMMT disclosed the FDA basically told them they need OS for approval. Well, we know the study they submitted for BLA didn't hit OS, and still hasn't hit OS, and even if it did it doesn't technically count if it didn't meet it by the designs of the trial and data cuts, why are people thinking approval has a good chance of happening when we know the trial they submitted didn't reach that goal? Not trying to be a bear, I know the typical response here is that the FDA takes a lot into consideration, but they literally told SMMT this time they're not doing that, and they need OS. Doesn't that kinda mean they won't get approval?
1 · Reply
danefiori
danefiori Aug. 21 at 3:35 PM
$SMMT 🚀
0 · Reply
danefiori
danefiori Aug. 21 at 2:59 PM
$SMMT massive insider buy of 3.81 million shares. Super bearish. We are within the 90 day FDA Approval window
1 · Reply
SmokeWagon
SmokeWagon Aug. 21 at 2:02 PM
$SMMT !!!
0 · Reply
BigBeardTrader
BigBeardTrader Aug. 21 at 2:00 PM
$SMMT It would be great to get some surprise Harmoni 3 data today
1 · Reply
TruthBroker2
TruthBroker2 Aug. 21 at 1:55 PM
0 · Reply
Megabyte48
Megabyte48 Aug. 21 at 1:21 PM
$SMMT loading more
0 · Reply
LeisureSuitLarry
LeisureSuitLarry Aug. 21 at 4:15 AM
0 · Reply
RadioIsotope25
RadioIsotope25 Aug. 21 at 1:14 AM
$RADX RAD204 has the type of asymmetric setup that an early $SMMT -like story requires: a huge established oncology target, an unconventional way of exploiting that target, encouraging human proof-of-mechanism, and an initial efficacy signal. The next ~5–10 evaluable patients are probably far more important than the first PR it just had. If RAD204 starts generating repeatable PRs—particularly in checkpoint-refractory NSCLC—then this analogy becomes considerably more serious. That's also where the valuation could change very quickly, because the market wouldn't merely be valuing another Lu-177 drug. It would potentially be valuing PD-L1 as a new radiopharmaceutical target class
0 · Reply
BapoRothstein
BapoRothstein Aug. 20 at 7:59 PM
$SMMT I don’t like Baker Bros trim into the FDA decision. Saying you’ll ride with Bob until the end is easy. There were points along the way in every one of Bob’s previous mega successes where investors who said they would ride with Bob all the way decided to bail and missed out on life changing wealth. Riding all the way through a pre-revenue biotech investment with your primary thesis based on the extraordinary nature of one man is really hard to do. There will always be peaks and valleys on the way to the finish line. Moments where people stop believing in the vision, stop being able to understand it, become overtaken by FUD, need money now, or simply get impatient, which causes them to bail. I understand all that and don’t fault anyone for it. But not me on this one. Riding with Bob means I’m riding with Bob. Through the peaks and valleys, the FUD, the hit jobs, news of other investors bailing, my own trading partner bailing, and all of it. Doesn’t matter. I’m riding with Bob.
3 · Reply
Boom1166
Boom1166 Aug. 20 at 7:57 PM
0 · Reply
EB2224
EB2224 Aug. 20 at 7:41 PM
$SMMT so looking forward to this going to $40, $50, $100 and shorts losing their…literal shorts
0 · Reply
TruthBroker2
TruthBroker2 Aug. 20 at 7:24 PM
$SMMT 12.88
0 · Reply
MoneyMacG
MoneyMacG Aug. 20 at 7:19 PM
0 · Reply
Nitroxic73
Nitroxic73 Aug. 20 at 6:29 PM
$MRNA if $SMMT succeeds with their studies the addressable market size is 10x+.
0 · Reply
REIoutdoorsHater
REIoutdoorsHater Aug. 20 at 6:08 PM
$SMMT Buying heavy here. Was here at 2.0 and sold at 6-7. 12 is a bargain with the development since then
0 · Reply